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Abstract: This study aims to evaluate the role of volume-based
positron emission tomography parameters as potential surrogate mar-
kers for tumor recurrence in resected pancreatic cancer.
Between January 2008 and October 2012, medical records of
patients who underwent surgical resection for pancreatic ductal adeno-
carcinoma and completed 18F-fluorodeoxyglucose positron emission
tomography/CT as a part of preoperative staging work-up were retro-
spectively reviewed. Not only clinicopathologic variables but also
positron emission tomography parameters such as SUVmax, MTV2.5
(metabolic tumor volume), and TLG (total lesion glycolysis) were
obtained.
Twenty-six patientswerewomen and 31weremenwith amean age of
62.9 9.1 years. All patients were preoperatively determined to resect-
able pancreatic cancer except 1 case with borderline resectability. R0
resection was achieved in all patients and 45 patients (78.9%) received
postoperative adjuvant chemotherapy with or without radiation therapy.
Median overall disease-free survival was 12.8 months with a median
overall disease-specific survival of 25.1months. SUVmax did not correlate
with radiologic tumor size (P¼ 0.501); however,MTV2.5 (P¼ 0.001) and
TLG (P¼ 0.009)were significantly associatedwith radiologic tumor size.
In addition, MTV2.5 (P< 0.001) and TLG (P< 0.001) were significantly
correlated with a tumor differentiation. There were no significant differ-
ences in TLG and SUVmax according to lymph node ratio; only MTV2.5
was related to lymph node ratiowithmarginal significance (P¼ 0.055). In
multivariate analysis, lymph node ratio (Exp [b]¼ 2.425, P¼ 0.025) and
MTV2.5 (Exp[b]¼ 2.273, P¼ 0.034) were identified as independent
predictors of tumor recurrence followingmargin-negative resection. Even
after tumor size-matched analysis, MTV was still identified as signifi-Ho Kyoung Hwan un, MD,
Lee, MD
Preoperatively determined volume-based PET parameter, MTV2.5,
can potentially be used as a surrogate marker to estimate tumor biology
and tumor recurrence. Individual treatment strategies for pancreatic
cancer can be suggested based on patients’ preoperative MTV2.5.
(Medicine 95(9):e2595)
Abbreviations: CT = computed tomography, FDG =
fluorodeoxyglucose, MRI = magnetic resonance imaging, MTV =
metabolic tumor volume, PET = positron emission tomography,
SUV = standard uptake value, TLG = total lesion glycolysis.
INTRODUCTION
P ancreatic cancer is one of the most lethal malignant tumorsarising from the gastrointestinal tract. Margin-negative
pancreatectomy is an essential step for cure of disease; however,
most patients arediagnosedatadvancedstagesof pancreatic cancer
that preclude curative resection. Even after R0 resection, most
patients experience systemic tumor recurrence and finally die due
to cancer progression. Therefore, further investigations are needed
to determine optimal strategies for early diagnosis, safe margin-
negative pancreatectomy, the stratification of patients in terms of
recurrence risk, and effective adjuvant treatment.
For the purpose of accurate and reliable clinical and
prognostic assessment, positron emission tomography (PET),
which has the benefit for revealing the information about
biological properties of tumors, has been frequently used in
clinical practice. In fact, PET has been shown to provide several
important clinical information about pancreatic cancer in terms
of differential diagnosis between benign and malignant neo-
plasms,1,2 preoperative staging,3,4 the evaluation of therapeutic
response,5,6 and the prediction of prognosis.7,8
Fluorine-18 fluorodeoxyglucose (18F-FDG) is metabolized
similarly to glucose in tumor cells, which is transported into a
cytoplasm through specific glucose transporters in cell mem-
brane and phosphorylated by hexokinase. However, phosphory-
lated FDG cannot be metabolized further; therefore, it
accumulates in tumor cells, forming the basis of tumor detection
via increased FDG uptake. 18F-FDG PET/CT has become an
important imaging modality in staging, restaging, and monitor-
ing of treatment responses in many malignant tumors, as it can
provide a quantification of tumor metabolic activity to clin-
icians. The standard uptake value (SUV) is a commonly used
semiquantitative parameter for the interpretation of PET
images. The maximum SUV (SUVmax), which can be calculated
from a 1-pixel region of interest corresponding to the maximum
pixel value in the tumor, is a very commonly used parameter forsis and assessing treatment responses.
known to be an observer-dependent
be influenced by the region of interest,
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which is usually determined by an observer.9,10 Furthermore, a
single pixel is unlikely to reflect the activity of metabolically
heterogeneous tumors accurately. In order to resolve these
clinical problems related to the use of SUVmax, several
volume-based PET parameters have been introduced to estimate
accurate and objective measurement of tumor biology.
Recently, metabolic tumor volume (MTV) and total lesion
glycolysis (TLG) were developed to measure the metabolic
activity of an entire tumor.11
In this study, we correlated these 2 volume-based PET
parameters with clinicopathologic characteristics of resected
pancreatic cancer and sought to establish whether these recently
developed PET parameters can estimate the risk of tumor
recurrence in pancreatic cancer after curative resection.
MATERIALS AND METHODS
Clinicopathologic Parameters
We retrospectively reviewed medical records of patients
who underwent potentially curative resection of pancreatic ductal
adenocarcinoma and completed preoperative 18F-FDG PET/CT
as part of a staging work-up between January 2008 and October
2012. Those who received preoperative neoadjuvant treatment
due to unresectable pancreatic cancer on preoperative imaging
modalities or who had undergone palliative surgery were
excluded from the study. However, the data set of patients with
neoadjuvant treatment followed by pancreatectomy was used for
evaluating the potential impact of neoadjuvant treatment on
biologic impact of PET-based parameters. All patients underwent
18F-FDG PET/CT and conventional radiologic examinations
including contrast-enhanced CTand/or magnetic resonance ima-
ging (MRI). Additionally, serum CA19–9 levels were measured
before treatment. This study was approved by the Institutional
Review Board at our institution, and written informed consent
was obtained from all patients. During the follow-up period,
patients were clinically assessed every 3 to 6 months by blood
tests including serumCA19–9 and contrast-enhanced abdomino-
pelvic CT. If the clinical assessment or follow-up studies revealed
abnormal findings, additional diagnostic studies and biopsy with
histopathologic confirmation were performed to evaluate cancer
recurrence. Clinicopathologic variables that were retrospectively
collected regarding gender, age, tumor location, operation type,
tumor size, grade (differentiation), pathologic tumor (pT) stage,
presence of lymph node metastasis, lymph node ratio (total
number of metastatic lymph nodes divided by total number of
retrieved lymph node), microscopic perineural invasion, lympho-
vascular invasion, recurrence pattern, and time to recurrence,
which was defined as the time from surgical resection to recur-
rence or last clinical follow-up visit at our medical center.
Volume-based PET parameter (MTV2.5 and TLG):
18F-
FDG PET/CT scans were performed with a dedicated PET/CT
scanner (Discovery STe, GE Healthcare; or Biograph TruePoint
40, Siemens Healthcare). All patients fasted for at least 6 hours
before the PET/CT scan. A dose of 5.5MBq/kg of 18F-FDG
was intravenously injected 60minutes before imaging. First, a
CT scan was performed at 30mA and 130 kVp for the Dis-
covery STe instrument, and 36mA and 120 kVp for Biograph
TruePoint instrument without contrast-enhancement. After the
CT scan was complete, a PET scan was performed for extending
from the neck to the proximal thighs with an acquisition time of
3min per bed position in 3D mode. PET images were recon-
Kang et alstructed using ordered subset expectation maximization
(OSEM) with an attenuation correction. 18F-FDG PET/CT
images were reviewed by 2 nuclear medicine physicians using
2 | www.md-journal.coman Advantage Workstation 4.4 (GE Medical Systems). Maxi-
mum standardized uptake value (SUVmax) andMTV2.5 on PET
images were measured using the volume viewer software. Each
tumor was examined with a spherical-shaped volume of interest
(VOI) that included the entire lesion in the axial, sagittal, and
coronal planes. By using CT images, 18F-FDG uptake of normal
organs such as the bowel, stomach, and liver was not included in
the VOI. The SUVmax of the VOI was calculated as (decay-
corrected activity/tissue volume)/(injected dose/body weight).
MTV2.5 was defined as the total tumor volume with an SUV 
2.5, and the MTVand mean SUVof the VOI were automatically
calculated. TLG was calculated as (mean SUV)T (MTV). In
patients with SUVmax< 2.5, MTV2.5 and TLG were not
measured.
Statistics
Continuous variables were described asmean standard devi-
ation, and categorical variables were described as a frequency (%).
Student’s t test, chi-squared tests with Fisher’s exact tests, and linear
regression analyseswere performed. Survival curveswere estimated
using theKaplan–Meiermethod to calculate cumulative recurrence-
free survival rates. Statistical analyses were performed using SPSS
20.0 for Windows (SPSS Inc, Chicago, IL). P values< 0.05 were
considered to be statistically significant. Propensity score matching
was performed for reducing confounding bias betweenMTV2.5 and
tumor size. Total populations were divided into 2 subgroups regard-
ing small and large tumor groups according to mean value of
pathologic tumor size which 2.4 cm (median and mean value of
tumor size) was selected as cut-off value. And then, logistic
regression was conducted to estimate propensity score of each
patient. In each of the small and large tumor groups, the matching
between high and low MTV2.5 patients were undergone by greedy
algorithmbasedoncalculatedpropensity score (1:2 ratiomatching in
small tumor group and 1:1matching ratio in large tumor group). The
comparisons of clinicopathologic factors between selected high and
low MTV2.5 patients in each tumor size group were performed in
terms of sex, age, tumor size, T stage, N stage, perineural invasion,
lymphovascular invasion, tumor differentiation, lymph node ratio,
and CA 19–9. Difference of disease-free survival between high and
lowMTV2.5 was calculated by the Kaplan–Meier method and log-
rank test to estimate the prognostic effect of MTV2.5 value in small
and large tumor groups.
RESULTS
Patient Demographics
Twenty-six patients were women and 31 were men with an
average age of 62.9 9.1 years. Only 1 patient was determined
to have a borderline resectable pancreatic cancer, and the others
were all resectable lesions. All patients underwent margin-
negative pancreatectomy. Most patients required pancreatico-
duodenectomy (41 patients, 71.9%). The clinicopathologic
characteristics are described in Table 1. Forty-five patients
(78.9%) received postoperative adjuvant chemotherapy with
or without radiation therapy. Median overall disease-free sur-
vival was 12.8 months (95% confidence interval: 9.2–16.3) and
median overall disease-specific survival was 25.1 months (95%
confidence interval: 15.3–34.9).
Correlation Between Radiologic Tumor Size and
Medicine  Volume 95, Number 9, March 2016PET Parameters
When correlating PET parameters and radiologic tumor
size, SUVmax had no association with radiologic tumor size
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Clinicopathologic Characteristics of Patients
Variables Frequency (%)
Age (y) 62.9 9.1
Gender Female/male 26 (45.6)/31 (54.4)
Tumor location Head/body/tail 40 (70.2)/14 (24.6)/3 (5.3)
Radiologic tumor size (cm) 2.3 0.7
Preoperative CA 19–9 483.4 1618.3
operation PD/PPPD/DPS/TP 6 (10.5)/35 (61.4)/13 (5.3)/3 (5.3)
Pathologic tumor size (cm) 2.4 0.8
pTstage T1/T2/T3/T4 2 (3.5)/2 (3.5)/53 (93)/0 (0)
pNstage N0/N1 26 (45.6)/31 (54.4)
Retrieved LN number 17.8 7.8
Metastatic LN number 1.3 2.1
PNI No/yes 16 (28.1)/41 (71.9)
LVI No/yes 36/(63.2)/21 (36.8)
Tumor grade Well/moderate/poor 9 (15.8)/42 (73.7)/6 (10.5)
Curative resection R0/R1/R2 57 (100)/0/0
30-day mortality 0 (0)
DPS¼ distal pancreatectomy with splenectomy, LVI¼ lymphovascular invasion, PD¼ pancreaticoduodenectomy, PPPD¼ pylorus preserving
atec
Medicine  Volume 95, Number 9, March 2016 MTV2.5 as a Surrogate Marker of PDAC(SUVmax¼ 0.419  radiologic tumor size (cm)þ 4.557,
R2¼ 0.010, P¼ 0.501). However, volume-based PET
parameters MTV2.5 (MTV2.5¼ 3.177  radiologic tumor size
(cm) – 2.343, R2¼ 0.213, P¼ 0.001) and TLG (TLG¼ 12.737
pancreaticoduodenectomy, PNI¼ perineural invasion, TP¼ total pancre radiologic tumor size (cm) – 9.596, R2¼ 0.149, P¼ 0.009),
were both significantly associated with radiologic tumor size
(Figure 1).
Correlation Between Lymph Node Ratio and PET
Parameters
There were no significance differences in SUVmax
(5.3 2.8 vs 5.1 2.6, P¼ 0.749), TMV2.5 (3.6 3.4 vs
5.2 5.1, P¼ 0.93), or TLG (13.1 14.5 vs 21.7 24.6,
P¼ 0.124) according to lymph node metastasis. However,
the lymph node ratio (LNR) was correlated with MTV2.5
(TMV2.5¼ 0.11  LNRþ 1.260, R2¼ 0.035, P¼ 0.055,
Figure 1 and Table 2), but not with TLG (R2¼ 0.037,
P¼ 0.158) and SUMmax (R2¼ 0.006, P¼ 0.555).
FIGURE 1. Correlation between volume-based PET parameters and r
MTV2.5 and lymph node ratio (C). PET¼positron emission tomograp
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Correlation Between Tumor Grade and PET
Parameters
Tumor grade was also significantly correlated with
volume-based PET parameters. The values of MTV2.5 and
TLG in well-differentiated pancreatic cancer were much lower
than those in moderately or poorly differentiated pancreatic
cancer (P< 0.05); however, there was no difference in SUVmax
between the 2 groups (P¼ 0.200, Table 2).
Predicting Tumor Recurrence in Resected
Pancreatic Cancer Without Neoadjuvant
Treatment
The results of univariate analysis indicate that gender
(P¼ 0.636), age (P¼ 0.301), lymph node status (pN-stage,
P¼ 0.558), lymphovascular invasion (P¼ 0.705), perineural
invasion (P¼ 0.838), tumor grade (P¼ 0.643), and postopera-
tomy.tive adjuvant treatment (P¼ 0.998) were not predictive of
tumor recurrence. In contrast, SUVmax (<5 vs  5, median
13.6 months vs 8.9 months, P¼ 0.077), TLG (<18 vs 18,
adiologic tumor size (A), (B) and potential associations between
hy, MTV¼metabolic tumor volume.
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In clinical oncology, biologic behavior of the cancer is
usually determined on the basis of pathologic examination of
resected surgical specimens. Increased tumor size,12 positive
TABLE 2. Association BetweenMTV2.5 and LymphNode Ratio (LNR) and Difference in PET Parameters According to Tumor Grade
Variable
Lymph Node Ratio (LNR)
<0.08 0.08 P Value
MTV2.5 <4.5 27 9 0.04
4.5 9 10
Tumor Grade (Differentiation)
PET Parameters Well (N¼ 9) ModerateþPoor (N¼ 48) P Value
SUVmax 4.1 1.9 5.4 2.8 0.200
MTV2.5 (cm
3) 1.5 1.6 5.0 4.6 <0.001
TLG (g) 5.3 6.7 20.0 21.7 <0.001
osit
Kang et al Medicine  Volume 95, Number 9, March 2016median 14.7 months vs 8.8 months, P¼ 0.017), MTV2.5 (<4.5
vs 4.5, median 12.9 months vs 8.8 months, P¼ 0.011),
radiologic tumor size (<2.5 vs 2.5, median 17.5 vs 7.3
months, P¼ 0.035), operation mode (pancreaticoduodenect-
omy vs pylorus preserving pancreaticoduodenectomy vs distal
pancreatectomy with splenectomy vs total pancreatectomy,
median 3.3 months vs 12.2 months, vs 14.7 months, vs 5.3
months, P¼ 0.01), lymph node ratio (<0.08 vs 0.08, median
15.0 months vs 8.8 months, P¼ 0.07), and both volume-based
PET parameters below a certain threshold (TLG< 18 AND
MTV2.5< 4.5 vs TLG 18 OR MTV2.5  4.5, median 14.7
months vs 8.8 months, P¼ 0.017) were found to predict tumor
recurrence after curative pancreatectomy.
In multivariate analysis, only lymph node ratio (0.08)
and MTV2.5 (4.5) were found to be independent prognostic
factors predicting tumor recurrence in resected pancreatic can-
cer without neoadjuvant chemo radiation therapy (Table 3).
In addition, disease-free survival varied significantly according
to these 2 risk factors (Combination 0; LNR< 0.08 AND
MTV2.5< 4.5, median 14.7 months, Combination 1; LNR0.08
0.08 AND MTV2.5< 4.5, OR LNR< 0.08 AND MTV2.54.5,
median 12.2 months, Combination 2, LNR0.08 AND
MTV2.54.5, median 6.1 months, P¼ 0.001, Figure 2).
Tumor-Size Matched Analysis to Validate
Oncologic Impact of MTV2.5
Oncologic impact ofMTV2.5 was evaluated again by tumor-
size matched analysis using propensity scores. There was no
significant clinicopathologic difference according to MTV
LNR¼ lymph node ratio, MTV¼metabolic tumor volume, PET¼ p
lesion glycolysis.2.5
(Table 4). However, regardless of tumor size, it was found that
MTV2.5 still played a significant role in determining tumor
recurrence in resected pancreatic cancer (P¼ 0.048 in small sized
TABLE 3. Multivariate Analysis for Tumor Recurrence in
Resected Pancreatic Cancer
Variables Exp (B)
95% Confidence
Interval P Value
LNR 0.08 2.425 1.119–5.254 0.025
MTV2.5 4.5 2.273 1.066–4.850 0.034
LNR¼ lymph node ratio, MTV¼metabolic tumor volume
4 | www.md-journal.compancreatic cancer (<2.5 cm), Figure 3(A), and P¼ 0.001 in large
sized pancreatic cancer (2.5 cm), Figure 3(B)).
Attenuating Adverse Oncologic Impact of
MTV2.5>–4.5 by Neoadjuvant Chemoradiation
Therapy: a Pilot Study
During the same study period, 30 patients with resectable
pancreatic cancer who underwent preoperative CT image were
found to undergo pancreatectomy following neoadjuvant che-
moradiation therapy. It was noted that adverse oncologic impact
of MTV2.54.5 were attenuated to show comparable oncologic
outcome with those with MTV2.5< 4.5 (disease-free survival,
24.9 months (95% CI: 15.9–34.1) vs 16.4 months (95% CI:
8.1–24.7), P¼ 0.210, Figure 4).
DISCUSSION
ron emission tomography, SUV¼ standard uptake value, TLG¼ totalFIGURE 2. Disease-free survivals according to a combination of
independent prognostic factors (MTV2.5 and LNR): Combination
0, MTV2.5<4.5 AND LNR<0.08; Combination1, MTV2.5<4.5
AND LNR0.08,nMTV2.5 4.5 AND LRN<0.08; Combination 2,
MTV2.5  4.5 AND LNR 0.08. LNR¼ lymph node ratio,
MTV¼metabolic tumor volume.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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tumor grade,15 positive lymphovascular16 or perineural inva-
sion,17 and positive margin-status18 represent aggressive tumor
behaviors in pancreatic cancer that lead to early treatment
failure and resistance to conventional chemotherapy. Determin-
ing these prognostic factors is a key component of developing
an effective and reasonable treatment strategy based on accurate
cancer biologic behavior. Considering the high frequency of
advanced and potentially systemic disease at the time of initial
diagnosis of pancreatic cancer,19 preoperative prediction of
early recurrence and aggressive biologic behavior of tumor
can inform the prognosis and help patients avoid unnecessary
surgery.
It was hypothesized that PET parameters could reflect not
only tumor burden, but also tumor biology, because 18F-FDG
uptake correlates with cellular proliferation20,21 and tumor
behavior6,7,22,45 in pancreatic cancer. According to our results,
preoperative volume-based PET parameters MTV2.5 and TLG
were found to represent some tumor biologic characteristics in
resected pancreatic cancer. In the present study, the conven-
tional PET parameter, SUVmax, did not correlate with radiologic
tumor size, lymph node ratio, or tumor differentiation. In
contrast, MTV2.5 and TLG were closely related to radiologic
tumor size, lymph node ratio, and tumor grade, suggesting the
clinical usefulness of these volume-based PET parameters for
predicting tumor recurrence and tailoring the treatment of
pancreatic cancer.
In this study, preoperative MTV2.5 and TLG were found to
reflect tumor biologic behavior and were shown to be prog-
nostic factors determining tumor recurrence in univariate
analysis. However, only MTV2.5 was identified as an indepen-
dent prognostic factor for predicting tumor recurrence among
preoperatively detectable clinical parameters. Tumors with
MTV2.5  4.5 were revealed to have a higher risk of recurrence
compared with tumors <4.5 (Exp (B)¼ 2.273, P¼ 0.034), a
similar risk to that found for lymph node ratio in multivariate
analysis (Exp (B)¼ 2.425, P¼ 025). Recently, the distribution
of metastatic lymph nodes among all retrieved lymph nodes
(lymph node ratio) has become a powerful prognostic factor for
pancreatic cancer.14,23–28 However, the LNR can only be
obtained from pathologic examination of resected surgical
specimens. Therefore, the preoperative volume-based PET
parameter, MTV2.5, can be a useful surrogate marker that can
predict tumor recurrence before surgical intervention, and may
even help oncologists counsel against surgery that would be
unlikely to benefit the patient. For example, even in ‘‘resect-
able’’ pancreatic cancer,29 neoadjuvant chemotherapy with or
without radiation therapy can be proposed as an alternative
treatment for pancreatic cancer with a preoperative MTV2.5 
4.5, or an oncologist may recommend postoperative adjuvant
treatment regardless of their pathological parameters. In fact,
patients (N¼ 2) with 2 independent prognostic factors (MTV2.5
 4.5 and LNR 0.08), who had no postoperative adjuvant
treatment typically showed early recurrence within 3 months
from curative resection, whereas recurrence was found to be
delayed in patients (N¼ 8) who had both 2 risk factors and
received postoperative adjuvant chemotherapy (data not shown,
P< 0.001).
It is one of the outstanding points of current study that
MTV2.5 was again evaluated by propensity score matching
analysis according to tumor size. It is well known that tumor
MTV2.5 as a Surrogate Marker of PDACsize can be one of the prognostic factors to impact on oncologic
outcome of resected pancreatic cancer.12,30–32 In the present
study, MTV2.5 also showed strong relationship with radiologic
www.md-journal.com | 5
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Kang et al Medicine  Volume 95, Number 9, March 2016tumor size (R2¼ 0.213, P¼ 0.001, Figure 1(A)). Radiologic
tumor size was found to be one of the prognostic factors to
predict tumor recurrence in univariate analysis (<2.5 vs 2.5,
median 17.5 vs 7.3 months, P¼ 0.035). Although MTV2.5 was
identified as an independent prognostic factor in multivariate
analysis, tumor size-matched analysis was performed again to
remove all possible confounding bias from radiologic tumor
size. MTV2.5 was still analyzed as significant determinant in
predicting disease-free survival in resected pancreatic cancer
(Table 4, and Figure 3). There have been several studies
evaluating the oncologic significance of MTV2.5 and TLG in
lung cancer,33 head and neck cancer,34,35 esophageal cancer,36
ovarian cancer,37 osteosarcoma,38 and colorectal cancer.39,40
Several previous studies have showed the efficacy of MTV2.5
FIGURE 3. Size-dependent propensity scorematched analysis for d
(A) and large (2.4 cm) tumor group (B). MTV¼metabolic tumoin predicting oncologic outcomes in various cancers. However,
to the best of the authors’ knowledge, there have been only a
few published clinical researches on the prognostic value of
FIGURE 4. Potential oncologic effect of neoadjuvnat treatment in
preoperative resectable pancreatic cancer with high MTV2.5
(MTV2.54.5). Neoadjuvant chemoradiation therapy attenuated
negative impact of preoperative highMTV2.5 on pancreatic cancer
recurrence following radical pancreatectomy. MTV¼metabolic
tumor volume.
6 | www.md-journal.comMTV2.5 in patients with resected pancreatic cancer. Even recent
studies41–43 successfully showing the potential oncologic role
of MTV2.5 in pancreatic cancer did not concern this possible
confounding effect from tumor size. On top of that, our study
showed that neoadjuvant chemoradiation therapy could attenu-
ate potential adverse effect of high MTV on recurrence of
resectable pancreatic cancer (Figure 4). Although this pilot
study is based on a small number of selected patients, it is
suggesting that preoperatively determined ‘‘resectable’’ pan-
creatic cancer can be treated in a different way according to
preoperative PET-based parameter. In general, neoadjuvant
chemoradiation therapy has performed usually based on ana-
tomic relationship between tumor and major vessel.44 Beyond
this anatomic relationship, clinical parameters representing
tumor biology, such as PET-based parameter, and CA 19–9
could be possibly used even in preoperative ‘‘resectable’’
pancreatic cancer for selecting patients who would be benefit
from neoadjuvant treatment followed by pancreatectomy. This
effort will be a back bone of patient-oriented surgical approach
to improve survival outcome and further study is mandatory to
prove our observation.
There are several limitations to the present study, including
retrospective study design, which can lead to significant selec-
tion bias even after case-matched comparisons. Therefore, these
encouraging results should be validated based on large-scale
prospective clinical data in the near future. Our study demon-
strated that preoperative MTV2.5 functions as a new, clinically
detectable surrogate marker can predict the recurrence of
pancreatic cancer following curative resection. In addition,
differences in molecular expression according to volume-based
se-free survival between highMTVand lowMTV in small (<2.4 cm)
lume.PET parameters such asMTV would be interesting topic to be2.5
further investigated to identify molecular mechanism in deter-
mining recurrence risk in resected pancreatic cancer.
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